Nanotechnology and glaucoma: Little particles for a big disease

Current Opinion in Ophthalmology

Volumn 24, Issue 2, 2013, Pages 130-135

  Pita Thomas, Daniel W ^a   Goldberg, Jeffrey L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Gene Therapy; Glaucoma; Microspheres; Nanoparticles

Indexed keywords

ALGINIC ACID; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CHITOSAN; EYE DROPS; GOLD NANOPARTICLE; HEAT SHOCK PROTEIN; MICROSPHERE; NANOPARTICLE;

ANTERIOR EYE SEGMENT; AQUEOUS HUMOR; BRONCHOSPASM; CENTRAL CORNEAL THICKNESS; CLINICAL TRIAL (TOPIC); CORNEA EPITHELIUM; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; ENDOCYTOSIS; EPITHELIUM; FATIGUE; GENE MUTATION; GENE THERAPY; GLAUCOMA; HUMAN; HYPOTENSION; INTRAOCULAR PRESSURE; NANOTECHNOLOGY; NERVE FIBER DEGENERATION; OPTIC NERVE; PATIENT COMPLIANCE; PIGMENT EPITHELIUM; POSTERIOR EYE SEGMENT; PRIORITY JOURNAL; RETINA GANGLION CELL; RETINA ISCHEMIA; REVIEW; SUBRETINAL NEOVASCULARIZATION; TIGHT JUNCTION; VIRAL GENE DELIVERY SYSTEM; VISUAL IMPAIRMENT; XEROSTOMIA;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DRUG CARRIERS; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; NANOPARTICLES; NANOTECHNOLOGY;

EID: 84876283807     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32835cfe92     Document Type: Review

References (68)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90:262-267.
2. Nakamura M, Kanamori A, Negi A. Diabetes mellitus as a risk factor for glaucomatous optic neuropathy. Ophthalmologica 2005; 219:1-10.
3. Herbert HM, Viswanathan A, Jackson H, Lightman SL. Risk factors for elevated intraocular pressure in uveitis. J Glaucoma 2004; 13:96-99.
4. Chang EE, Goldberg JL. Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement. Ophthalmology 2012; 119:979-986. This review describes the current treatments for glaucoma and the possible new directions for the field that extend beyond intraocular pressure management.
5. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004; 363: 1711-1720.
6. Crooks KR, Allingham RR, Qin X, et al. Genome-wide linkage scan for primary open angle glaucoma: influences of ancestry and age at diagnosis. PLoS One 2011; 6:e21967.
7. Jiao X, Yang Z, Yang X, et al. Common variants on chromosome 2 and risk of primary open-angle glaucoma in the Afro-Caribbean population of Barbados. Proc Natl Acad Sci USA 2009; 106:17105-17110.
8. Rochtchina E, Mitchell P, Wang JJ. Relationship between age and intraocular pressure: the Blue Mountains Eye Study. Clin Exp Ophthalmol 2002; 30: 173-175.
9. Wong TT, Wong T Y, Foster P J, et al. The relationship of intraocular pressure with age, systolic blood pressure, and central corneal thickness in an Asian population. Invest Ophthalmol Vis Sci 2009; 50:4097-4102.
10. Kuzin AA, Varma R, Reddy HS, et al. Ocular biometry and open-angle glaucoma: the Los Angeles Latino Eye Study. Ophthalmology 2010; 117: 1713-1719.
11. Mitchell P, Lee AJ, Rochtchina E, Wang JJ. Open-angle glaucoma and systemic hypertension: the Blue Mountains Eye Study. J Glaucoma 2004; 13: 319-326.
12. Leske MC, Wu SY, Hennis A, et al. Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. Ophthalmology 2008; 115:85-93.
13. Burgoyne CF, Downs JC. Premise and prediction-how optic nerve head biomechanics underlies the susceptibility and clinical behavior of the aged optic nerve head. J Glaucoma 2008; 17:318-328.
14. Fingert JH. Primary open-angle glaucoma genes. Eye (Lond) 2011; 25:587-595.
15. Resch ZT, Fautsch MP. Glaucoma-associated myocilin: a better understanding but much more to learn. Exp Eye Res 2009; 88:704-712.
16. Chi ZL, Akahori M, Obazawa M, et al. Overexpression of optineurin E50K disrupts Rab8 interaction and leads to a progressive retinal degeneration in mice. Hum Mol Genet 2010; 19:2606-2615.
17. Yanagi M, Kawasaki R, Wang JJ, et al. Vascular risk factors in glaucoma: a review. Clin Exp Ophthalmol 2011; 39:252-258.
18. Cherecheanu AP, Garhofer G, Schmidl D, et al. Ocular perfusion pressure and ocular blood flow in glaucoma. Curr Opin Pharmacol 2012 (in press).
19. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 1998; 126:487-497.
20. Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology 2006; 113:431-436.
21. Reardon G, Kotak S, Schwartz GF. Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence 2011; 5:441-463.
22. Gurwitz JH, Glynn RJ, Monane M, et al. Treatment for glaucoma: adherence by the elderly. Am J Public Health 1993; 83:711-716.
23. Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005; 140:598-606.
24. Loch C, Zakelj S, Kristl A, et al. Determination of permeability coefficients of ophthalmic drugs through different layers of porcine, rabbit and bovine eyes. Eur J Pharm Sci 2012; 47:131-138.
25. Rittenhouse KD, Peiffer RL Jr., Pollack GM. Evaluation of microdialysis sampling of aqueous humor for in vivo models of ocular absorption and disposition. J Pharm Biomed Anal 1998; 16:951-959.
26. Wei G, Xu H, Ding PT, et al. Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies. J Control Release 2002; 83:65-74.
27. Hamalainen KM, Kananen K, Auriola S, et al. Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest Ophthalmol Vis Sci 1997; 38:627-634.
28. Lavik E, Kuehn MH, Kwon YH. Novel drug delivery systems for glaucoma. Eye (Lond) 2011; 25:578-586.
29. Wei G, Ding PT, Zheng JM, Lu WY. Pharmacokinetics of timolol in aqueous humor sampled by microdialysis after topical administration of thermosetting gels. Biomed Chromatogr 2006; 20:67-71.
30. Sena DF, Ramchand K, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev 2010; (2):CD006539. [Review].
31. Krupin T, Liebmann JM, Greenfield DS, et al. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol 2011; 151:671-681.
32. Quigley HA. Clinical trials for glaucoma neuroprotection are not impossible. Curr Opin Ophthalmol 2012; 23:144-154.
33. Acheampong AA, Shackleton M, Tang-Liu DD, et al. Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs. Curr Eye Res 1999; 18:91-103.
34. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med 2006; 355:1419-1431.
35. Sunshine JC, Sunshine SB, Bhutto I, et al. Poly(beta-amino ester)-nanoparticle mediated transfection of retinal pigment epithelial cells in vitro and in vivo. PLoS One 2012; 7:e37543.
36. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54 (Suppl. 1):S131-S155. [Review].
37. Tamboli V, Mishra GP, Mitrat AK. Polymeric vectors for ocular gene delivery. Ther Deliv 2011; 2:523-536. This review compares nanoparticles and viruses as gene delivery vectors.
38. Wang J, Huang Y, David AE, et al. Magnetic nanoparticles for MRI of brain tumors. Curr Pharm Biotechnol 2012 (in press).
39. Chen J, Patil S, Seal S, McGinnis JF. Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nat Nanotechnol 2006; 1:142-150.
40. Gref R, Domb A, Quellec P, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev 1995; 19:215-233.
41. Venishetty VK, Komuravelli R, Kuncha M, et al. Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles. Nanomed 2012 (in press).
42. Tosi G, Fano RA, Bondioli L, et al. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier. Nanomed 2011; 6:423-436.
43. Kompella UB, Sundaram S, Raghava S, Escobar ER. Luteinizing hormonereleasing hormone agonist and transferrin functionalizations enhance nanoparticle delivery in a novel bovine ex vivo eye model. Mol Vis 2006; 12:1185-1198.
44. De Campos AM, Sanchez A, Alonso MJ. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm 2001; 224:159-168.
45. Nagarwal RC, Kumar R, Pandit JK. Chitosan coated sodium alginate-chitosan nanoparticles loaded with 5-FU for ocular delivery: in vitro characterization and in vivo study in rabbit eye. Eur J Pharm Sci 2012; 47:678-685. In this article, adding sodium alginate to chitosan nanoparticles doubled the rabbit aqueous humor bioavailability of the pyrimidine analog 5-fluorouracil. This modification demonstrates the potential value of increasing drug mucoadhesiveness to and persistence at the cornea.
46. Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation. J Drug Target 2010; 18:292-302.
47. Bhagav P, Upadhyay H, Chandran S. Brimonidine tartrate-eudragit longacting nanoparticles: formulation, optimization, in vitro and in vivo evaluation. AAPS PharmSciTech 2011; 12:1087-1101. Here, the authors optimized the characteristics of Eudragit nanoparticles for releasing the drug brimonidine. The optimal Eudragit nanoparticles increased drug half-life in the cornea and produced a 72-h reduction of IOP in rabbits, significantly longer than the 8 h achieved by the unmodified drug.
48. Kadam RS, Tyagi P, Edelhauser HF, Kompella UB. Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide. Int J Pharm 2012; 434:140-147. This study demonstrated that microspheres injected subconjuctivally in rats lasted for 2 months in that location, releasing drug in ocular structures.
49. Bertram JP, Saluja SS, McKain J, Lavik EB. Sustained delivery of timolol maleate from poly(lactic-co-glycolic acid)/poly(lactic acid) microspheres for over 3 months. J Microencapsul 2009; 26:18-26.
50. Danion A, Brochu H, Martin Y, Vermette P. Fabrication and characterization of contact lenses bearing surface-immobilized layers of intact liposomes. J Biomed Mater Res A 2007; 82:41-51.
51. Checa-Casalengua P, Jiang C, Bravo-Osuna I, et al. Retinal ganglion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure. J Control Release 2011; 156:92-100. In this study, GDNF neuroprotection in rat RGCs was prolonged for several months using a novel microsphere formulation that protects and slowly releases this neurotrophic factor.
52. Jiang C, Moore MJ, Zhang X, et al. Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol Vis 2007; 13:1783-1792.
53. Jeun M, Jeoung JW, Moon S, et al. Engineered superparamagnetic Mn0.5Zn0.5Fe2O4 nanoparticles as a heat shock protein induction agent for ocular neuroprotection in glaucoma. Biomaterials 2011; 32:387-394. The goal of this study was to induce heat shock proteins to protect RGCs from degeneration. The authors optimize metallic nanoparticles for producing controlled heat when a magnetic field is applied, and demonstrate that after intravitreal injection in rats the nanoparticle distribution is close enough to induce hyperthermia inRGCs.
54. Kitagawa K, Matsumoto M, Tagaya M, et al. Hyperthermia-induced neuronal protection against ischemic injury in gerbils. J Cereb Blood Flow Metab 1991; 11:449-452.
55. Zhou X, Wong LL, Karakoti AS, et al. Nanoceria inhibit the development and promote the regression of pathologic retinal neovascularization in the Vldlr knockout mouse. PLoS One 2011; 6:e16733. The authors took advantage of the antioxidant properties of cerium oxide nanoparticles to revert the retinal neovascularization in Vldlr knockout mice.
56. Whitmore AV, Libby RT, John SW. Glaucoma: thinking in new ways-a role for autonomous axonal self-destruction and other compartmentalised processesProg Retin Eye Res 2005; 24:639-662.
57. Goldberg JL, Barres BA. The relationship between neuronal survival and regeneration. Annu Rev Neurosci 2000; 23:579-612.
58. Pita-Thomas W, Steketee MB, Hampton B, Goldberg JL. Synaptotagmin vesicle trafficking to the nerve injury site. Implications for injury sealing and new growth cone formation. Cold Spring Harbor Meeting on Axonal Guidance, Synapse Formation and Regeneration. [Poster]. 2012.
59. Bernstein SL, Johnson MA, Miller NR. Nonarteritic anterior ischemic optic neuropathy (NAION) and its experimental models. Prog Retin Eye Res 2011; 30:167-187.
60. Wang Y, Brown DPJ, Duan Y, et al. A novel rodent model of posterior ischemic optic neuropathy. Arch Ophthalmol 2012; 8:1-11.
61. Borras T, Brandt CR, Nickells R, Ritch R. Gene therapy for glaucoma: treating a multifaceted, chronic disease. Invest Ophthalmol Vis Sci 2002; 43:2513-2518.
62. Borras T. Advances in glaucoma treatment and management: gene therapy. Invest Ophthalmol Vis Sci 2012; 53:2506-2510.
63. Han Z, Conley SM, Naash MI. AAV and compacted DNA nanoparticles for the treatment of retinal disorders: challenges and future prospects. Invest Ophthalmol Vis Sci 2011; 52:3051-3059.
64. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003; 55:329-347.
65. Koo H, Moon H, Han H, et al. The movement of self assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection. Biomaterials 2012; 33:3485-3493. This article demonstrates that the retinal distribution of intravitreally injected nanoparticles depends on the nature of their chemical structures.
66. Park K, Chen Y, Hu Y, et al. Nanoparticle mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes 2009; 58:1902-1913.
67. Steketee MB, Moysidis SN, Jin XL, et al. Nanoparticle-mediated signaling endosome localization regulates growth cone motility and neurite growth. Proc Natl Acad Sci USA 2011; 108:19042-19047. This study demonstrates that 50nm iron oxide nanoparticles functionalized with an agonist trkB antibody are endocytosed by rat RGCs in vitro and in vivo after intravitreal injection and can be used to modulate axon growth when a magnetic field is applied.
68. Farjo R, Skaggs J, Quiambao AB, et al. Efficient nonviral ocular gene transfer with compacted DNA nanoparticles. PLoS One 2006; 1:e38.